

## Guideline Session II: Prostate cancer - cN+ in newly diagnosed patients

Live from the studio: Thematic Session 14

**Sunday 11 July**  
**15:00 - 16:00**

**Location** Virtual Room 2

**Chairs**  
A. Breda, Barcelona (ES)  
P. Cornford, Liverpool (GB)  
N. Mottet, Saint-Étienne (FR)

### Learning objectives

In a newly diagnosed M0 prostate cancer, finding suspicious nodes on imaging leads to the optimal treatment sequence. Recently conventional imaging has been surpassed by newer imaging modalities. However what is the clinical meaning of such findings and to what extent is this associated with a treatment change? If the optimal treatment usually includes a local therapy, the optimal combined systemic therapy needs clarification, especially regarding adding something on top of ADT: what is the real benefit of drug combination, if any?

**15:00 - 15:05**

**Introduction cN+: What does it mean?**  
N. Mottet, Saint-Étienne (FR)

**15:05 - 15:24**

**cN+ and imaging**

**15:05 - 15:12**

**What are we talking about?**  
W.J.G. Oyen, Arnhem (NL)

**15:12 - 15:19**

**Guidelines Point of view cN+ = pN+?**  
J. Grummet, Melbourne (AU)

**15:19 - 15:24**

**Discussion**

**15:24 - 15:43**

**cN+ and systemic treatment**

**15:24 - 15:31**

**More than ADT is needed as systemic TTT: Yes!**  
M. De Santis, Berlin (DE)

**15:31 - 15:38**

**Guidelines Point of view More than ADT is needed as systemic TTT: No!**  
G. Ploussard, Toulouse (FR)

**15:38 - 15:43**

**Discussion**

**15:43 - 15:55**

**cN+ and local treatment**

**15:43 - 15:50**

**Guidelines Point of view**  
T. Wiegel, Ulm (DE)

**15:50 - 15:55**

**Discussion**

**15:55 - 16:00**

**Closing remarks**  
P. Cornford, Liverpool (GB)